Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company

Research will assess the combination of Avicanna’s proprietary SEDDS technology in various drug delivery systems and dosage forms

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce it has entered into a research collaboration with a multi-national European-based pharmaceutical company (“Collaborator”).

The research collaboration will initially assess the Company’s proprietary SEDDS technology in combination with Collaborator’s various drug delivery and pharmaceutical formats to gain a better understanding of proprietary dosage forms with precisely standardized delivery and enhanced bioavailability of cannabinoids. The research collaboration may subsequently assess the possibility of further preclinical research and clinical development. Under the research collaboration, Avicanna will also provide services for assessing a range of other formulations that may be included in Collaborator’s portfolio.

About the SEDDS Technology

Due to the highly lipophilic nature and poor water-solubility of cannabinoids, the formulations currently available in the Canadian market have been generally described as having poor absorption and high variability of onset. Avicanna’s proprietary SEDDS oral delivery systems offer an effective route for non-invasive and non-inhalation administration of cannabinoids^1-4. With SEDDS drug delivery system it is expected that the daily intake and frequency of administration of cannabinoid-based medicine could be significantly reduced. Avicanna’s SEDDS technology has demonstrated robustness and versatility through different drug delivery formats including liquid infuser drops, already commercialized in Canada, solid capsule form in commercialization stage and powder form with tunable release which is dedicated for pharmaceutical dosage forms.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments: